Aspen Neuroscience Inc., a clinical-stage developer of cell therapies supported by Gilead, sees its shares fall about 2% following a US initial public offering. Bloomberg reports the decline on the day of trading after the company raises roughly $140.6 million.
Investing.com says the IPO is priced at $15 per share, adding detail on the offer terms. While the outlets differ in emphasis—one focusing on post-IPO share movement and the other on the pricing—both describe the same event: Aspen Neuroscience’s recent US listing and the initial market response.
Taken together, the coverage points to a newly public biotech company entering the market at a stated $15 offer price, then experiencing modest early trading weakness immediately after completing its IPO process.